isis loses patent challenge

I wonder what does this latest news means for ANP (if anything?)

United States Patent and Trademark Office (USPTO) rules in favor of Santaris Pharma A/S in patent re-examination cases for two key Santaris Pharma A/S "Imanishi" patents
- Patents cover the 2'-4' bicyclic nucleotides known as LNA (Locked Nucleic Acid) or BNA (Bicyclic Nucleic Acid) chemistry that Santaris Pharma A/S has successfully developed to generate effective RNA-targeted therapies for a wide range of diseases
- Santaris Pharma A/S LNA Drug Platform is rapidly becoming the technology-of-choice for partners interested in developing RNA-targeted medicines for unmet medical needs